Chunling Dong

Prof. Dr. Chunling Dong


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Medicine
Verified
Journal Article
Open access
NLNa Liu
Na Liu
JMJinmei Mao
Jinmei Mao
PTPeizhi Tao
Peizhi Tao
HCHao Chi
Hao Chi
WJWenhui Jia
Wenhui Jia
CDChunling Dong
Chunling Dong
Background: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) and the dire prognosis of non-small cell lung carcinoma patients who received immune checkpoint inhibitors (ICIs) are not known yet. Methods: We screened the articles that meet the criteria from the database. The relationship between NLR/PLR/LMR levels and the survival and prognosis of non-small cell lung cancer patients treated with ICIs was analyzed. Summarize hazard ratio (HR) with 95% confidence interval (CI) to study progression-free survival (PFS) and overall survival (OS). Results: Thirty-four studies involving 3124 patients were enrolled in the final analysis. In short, high pre-treatment NLR was related to poor OS (HR = 2.13, 95% CI:1.74–2.61, P < .001, I2 = 83.3%, P < .001) and PFS (HR = 1.77, 95% CI:1.44–2.17, P < .001, I2 = 79.5%, P < .001). Simultaneously, high pre-treatment PLR was related to poor OS (HR = 1.49, 95% CI:1.17–1.91, P < .001, I2 = 57.6%, P = .003) and PFS (HR = 1.62, 95% CI:1.38–1.89, P < .001, I2 = 47.1%, P = .036). In all subgroup analysis, most subgroups showed that low LMR was related to poor OS (HR = 0.45, 95% CI: 0.34–0.59, P < .001) and PFS (HR = 0.60, 95% CI: 0.47–0.77, P < 0.001, I2 = 0.0%, P < .001). Conclusion: High pre-treatment NLR and pre-treatment PLR in non-small cell lung carcinoma patients treated with ICIs are associated with low survival rates. Low pre-treatment and post-treatment LMR are also related to unsatisfactory survival outcomes. However, the significance of post-treatment NLR and post-treatment PLR deserve further prospective research to prove.

1 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
WJWenhui Jia
Wenhui Jia
CDChunling Dong
Chunling Dong
Bo LiBo Li
Bo Li
Peroxiredoxin 6 (PRDX6) is widely distributed in several organs, especially the lungs. The role of PRDX6 in oxidative stress is controversial and even contradictory, as indicated by research conducted over the past 20 years. PRDX6 has anti-oxidant or pro-oxidant effects on oxidative stress in different diseases. It can even exhibit both anti-oxidant and pro-oxidant effects in the same disease. These findings are attributed to the fact that PRDX6 is a multifunctional enzyme. The peroxidase and phospholipase A2 activity of PRDX6 is closely related to its anti-oxidant and pro-oxidant effects, which leads to the conflicting regulatory effects of PRDX6 on oxidative stress in respiratory diseases. Moreover, PRDX6 interacts with multiple redox signaling pathways to interfere with cell proliferation and apoptosis. PRDX6 has become a new target in respiratory disease research due to its important regulatory role in oxidative stress. In this paper, the role of PRDX6 in oxidative stress in respiratory diseases and the research progress in targeting PRDX6 are reviewed.

4 April 2024 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
WJWenli Jiang
Wenli Jiang
WJWenhui Jia
Wenhui Jia
CDChunling Dong
Chunling Dong
As an autoimmune disease, the persistent systemic inflammatory response associated with connective tissue disease (CTD) is involved in the development of venous thromboembolism (VTE). However, clinical data showed that the risk of VTE in patients differed between subtypes of CTD, suggesting that different subtypes may have independent mechanisms to promote the development of VTE, but the specific mechanism lacks sufficient research at present. The development of pulmonary fibrosis also contributes to the development of VTE, and therefore, patients with CTD-associated interstitial lung disease (CTD-ILD) may be at higher risk of VTE than patients with CTD alone or patients with ILD alone. In addition, the activation of the coagulation cascade response will drive further progression of the patient’s pre-existing pulmonary fibrosis, which will continue to increase the patient’s risk of VTE and adversely affect prognosis. Currently, the treatment for CTD-ILD is mainly immunosuppressive and antirheumatic therapy, such as the use of glucocorticoids and janus kinase-inhibitors (JAKis), but, paradoxically, these drugs are also involved in the formation of patients’ coagulation tendency, making the clinical treatment of CTD-ILD patients with a higher risk of developing VTE challenging. In this article, we review the potential risk factors and related mechanisms for the development of VTE in CTD-ILD patients to provide a reference for clinical treatment and prevention.

16 January 2024 in World Journal of Clinical Cases
Verified
Journal Article
Open access
SFShan-Li Feng
Shan-Li Feng
JLJun-Yao Li
Jun-Yao Li
CDChunling Dong
Chunling Dong
There are few cases of pulmonary granulomatous changes secondary to primary biliary cirrhosis (PBC). No case of granulomatous lung disease secondary to PBC misdiagnosed as lung cancer had been reported. A middle-aged woman presented with lung nodules and was misdiagnosed with lung cancer by positron emission tomography/computed tomography. She underwent left lobectomy, and the pathology of the nodules showed granulomatous inflammation, which was then treated with antibiotics. However, a new nodule appeared. Further investigation with lung biopsy and liver serology led to the diagnosis of PBC, and chest computed tomography indicated significant reduction in the pulmonary nodule by treatment with methylprednisolone and ursodeoxycholic acid. Diagnosis of pulmonary nodules requires integrating various clinical data to avoid unnecessary pulmonary lobectomy.

8 September 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
CLChengyang Liu
Chengyang Liu
WJWenhui Jia
Wenhui Jia
SJSiyuan Jing
Siyuan Jing
CDChunling Dong
Chunling Dong
Chronic obstructive pulmonary disease (COPD) substantially increases the risk of lung cancer, yet biomarkers capable of identifying malignant transition before radiological abnormalities become evident remain lacking. Respiratory omics has emerged as a promising non-invasive approach for monitoring dynamic molecular alterations during disease progression through the analysis of exhaled volatile organic compounds (VOCs) and exhaled breath condensate (EBC). This review summarizes current evidence on respiratory biomarkers associated with COPD-to-lung cancer transition, emphasizing the biological mechanisms underlying their dynamic evolution and their potential applications in early detection and risk stratification. Rather than considering COPD and lung cancer as separate diseases, we discuss respiratory biomarker changes across the disease continuum and highlight their translational value for identifying high-risk individuals. Finally, we outline the major challenges limiting clinical implementation, including biomarker standardization and prospective validation, and discuss future directions involving multi-omics integration, artificial intelligence, and precision surveillance. Respiratory omics has the potential to advance non-invasive risk assessment and facilitate earlier intervention for COPD-associated lung cancer.

4 August 2025 in Respirology Case Reports
Verified
Journal Article
Open access
RGRong Gao
Rong Gao
JYJinyan Yu
Jinyan Yu
XLXuejiao Lv
Xuejiao Lv
CDChunling Dong
Chunling Dong
Primary pulmonary nuclear protein in testis (NUT) midline carcinoma (NMC) is a rare malignancy with characteristics that resemble those of squamous cell carcinoma, thus making it prone to both misdiagnosis and missed diagnosis. Primary pulmonary NMC is highly malignant and associated with poor prognosis, with no standardised effective treatments for patients who cannot undergo surgery. Concurrent or sequential chemoradiotherapy is considered an effective approach, and some targeted drugs have been clinically tested and demonstrated favourable results. We present a case of primary pulmonary NMC with cervical lymph node metastasis, in which the patient experienced temporary symptom relief after receiving anlotinib and chemotherapy combined with immunotherapy. However, the condition rapidly worsened, and the patient died within 1 month of diagnosis. We believe that combining anlotinib with chemotherapy as well as reducing the chemotherapy interval can be effective in the treatment of primary pulmonary NMC.